Is Cytosorbents going out of business?

CYTOSORBENTS CORPORATION (CTSO) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

CYTOSORBENTS CORPORATION (CTSO) scores 17 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)

Five questions, kept separate

Survival - Critical

2-4 mo of estimated runway from 2026-06-30, based on $4.4M of cash and short-term investments against $15.5M of annual burn. Debt pressure is the other decisive risk.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

-125% net-cash backing support an extreme expectations pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Cash Runway (years): 0.29y
• Return on Assets: -47.98%
• Revenue growth YoY: 0.17% (YoY)
• FCF margin: -41.61% (Inv. Mode)
• Revenue CAGR (3Y): 2.23%
• Debt Maturity Runway: 18% long-term (Near-term refinancing risk)
• Cash Burn Deceleration: -38.85% QoQ improvement (Worsening)
• Price / Sales: 0.5x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Shares dilution YoY: 1.78% (YoY)
• R&D intensity: 6.66%

Read from filings through 2026-08-06.

Price as of 2026-09-07.